Видео ютуба по тегу Secukinumab

Efficacy and safety of secukinumab in psoriasis over 5 years, R. Langley et al.
Efficacy and safety of secukinumab in psoriasis over 5 years, R. Langley et al.
Secukinumab Effect on CV Risks in PsA, axSpA: Dr. Sheila Reyes: Dr. Sheila Reyes
Secukinumab Effect on CV Risks in PsA, axSpA: Dr. Sheila Reyes: Dr. Sheila Reyes
Secukinumab individualized dosing in chronic plaque psoriasis, K. Reich et al
Secukinumab individualized dosing in chronic plaque psoriasis, K. Reich et al
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
How Cosentyx (secukinumab) Works in Plaque Psoriasis
How Cosentyx (secukinumab) Works in Plaque Psoriasis
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
Dr. Olga Petryna at EULAR 2018 on Pregnancy Outcomes with Secukinumab
Dr. Olga Petryna at EULAR 2018 on Pregnancy Outcomes with Secukinumab
Video Abstract: Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis
Video Abstract: Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis
Dr. Atul Deodhar - Treating AS with Secukinumab
Dr. Atul Deodhar - Treating AS with Secukinumab
Early Intervention with Secukinumab May Affect the Establishment of Tissue Memory in Psoriasis
Early Intervention with Secukinumab May Affect the Establishment of Tissue Memory in Psoriasis
Secukinumab in patients with psoriatic arthritis and axial manifestations
Secukinumab in patients with psoriatic arthritis and axial manifestations
Flexible dosing of secukinumab in patients with psoriasis weighing ≥90 kg, M. Augustin et al
Flexible dosing of secukinumab in patients with psoriasis weighing ≥90 kg, M. Augustin et al
Secukinumab [THU0325] ( Part 1) - Psoriatic Arthritis Posters and Abstracts from Amsterdam
Secukinumab [THU0325] ( Part 1) - Psoriatic Arthritis Posters and Abstracts from Amsterdam
Long-term efficacy of secukinumab in palmoplantar psoriasis, A.B. Gottlieb et al
Long-term efficacy of secukinumab in palmoplantar psoriasis, A.B. Gottlieb et al
Secukinumab (Cosentyx) rapidly effective against Ankylosing Spondylitis *NEW DRUG* 2015
Secukinumab (Cosentyx) rapidly effective against Ankylosing Spondylitis *NEW DRUG* 2015
IDEF Educational Series The Latest Approved Indication for COSENTYX® secukinumab
IDEF Educational Series The Latest Approved Indication for COSENTYX® secukinumab
Webinar Implication of Secukinumab therapies in Psoriatic Disease conditions
Webinar Implication of Secukinumab therapies in Psoriatic Disease conditions
Secukinumab is effective In Moderate To Severe Plaque Psoriasis When Compared To Ustekinumab
Secukinumab is effective In Moderate To Severe Plaque Psoriasis When Compared To Ustekinumab
Stability of response to secukinumab over 52 weeks, M. Augustin et al
Stability of response to secukinumab over 52 weeks, M. Augustin et al
IDEF Educational Series The Latest Approved Indication for COSENTYX secukinumab
IDEF Educational Series The Latest Approved Indication for COSENTYX secukinumab